The anticoagulant mechanism of Rivaroxaban

Rivaroxaban inhibits free and bound factor Xa in the prothrombinase complex. It is a selective direct factor Xa inhibitor with an onset time of 2.5-4 hours. Inhibitor factor Xa interrupts the intrinsic and extrinsic pathways of the blood coagulation cascade, inhibiting thrombin formation and thrombus formation. Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. It allows for predictable anticoagulation and dose adjustment as well as routine coagulation monitoring; no dietary restrictions are required.

Rivaroxaban has predictable pharmacokinetics in a broad range of patients and a flat dose response over an eight-fold dose range (5-40 mg). Oral bioavailability is dose dependent. Rivaroxaban in doses up to 10 mg can be taken with or without food, as rivaroxaban exhibits high bioavailability with or without food. If the oral dose of rivaroxaban is 15 mg or 20 mg, it needs to be taken with food to aid drug absorption and achieve appropriate bioavailability (≥80%).

RivaroxabanThe original drug is already on the market in China and can be found under Class B medical insurance. SpecificationsThe price of 10mg*5 tablets is around RMB 100. This drug may be sold in domestic pharmacies or hospitals. The Turkish version of rivaroxabanoriginal drug marketed overseas, specifications10mg*10 tablets, is priced around RMB 170 (the price may fluctuate due to exchange rates). The ingredients of the original rivaroxaban drug sold domestically and abroad are basically the same. Currently, there are no generic drugs produced in other countries on the market overseas.